Company Overview

Zoetis Inc. is a global animal health company focused on the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products, biologics, genetic tests, and precision animal health technologies for livestock and companion animals. The company operates within the broader animal health and veterinary pharmaceuticals industries and serves veterinarians, livestock producers, pet owners, and animal health distributors. Its primary revenue drivers include products for dogs, cats, cattle, swine, poultry, fish, and sheep, with companion animal products representing a significant and growing portion of revenue based on recent public filings and investor disclosures.

The company traces its origins to Pfizer’s animal health division, which was established in 1952. Zoetis became a standalone public company in 2013 following an initial public offering and subsequent separation from Pfizer. Since becoming independent, Zoetis has expanded through product innovation, acquisitions, and investment in diagnostics and digital veterinary technologies. The company is widely recognized for its diversified animal health portfolio, strong veterinary relationships, global manufacturing network, and recurring demand characteristics tied to companion animal care and food production industries.

Business Operations

Zoetis organizes operations primarily across product categories serving both companion animals and livestock. Its portfolio includes parasiticides, dermatology treatments, anti-infectives, vaccines, pain management therapies, diagnostics, and genetic testing solutions. Key product families include Apoquel, Cytopoint, Simparica, Librela, Solensia, and livestock vaccine lines. The company generates revenue through direct sales to veterinarians and livestock producers as well as through distributors and retail channels. Companion animal products account for the majority of sales growth, while livestock products provide diversification across global protein markets.

The company maintains operations across more than 100 countries and controls a broad network of manufacturing facilities, research centers, and commercial operations. Strategic assets include veterinary diagnostics capabilities through Abaxis, genetic testing and animal data services through Basepaws and related businesses, and biologics and vaccine production infrastructure. Zoetis also collaborates with veterinary clinics, research institutions, and agricultural stakeholders to support animal disease management and productivity initiatives. Public disclosures indicate the company continues to invest heavily in research and development to sustain long-term product pipelines.

Strategic Position & Investments

Zoetis has emphasized growth through innovation in companion animal therapeutics, expansion of diagnostics and precision animal health, and lifecycle management of established products. The company has prioritized dermatology, pain management, parasiticides, and monoclonal antibody therapies, areas viewed by management as high-growth segments within veterinary medicine. Recent launches such as Librela for canine osteoarthritis pain and Solensia for feline osteoarthritis have strengthened its positioning in biologic pain therapeutics.

The company has also expanded through acquisitions and strategic investments. Notable transactions include the acquisition of Abaxis, which strengthened point-of-care veterinary diagnostics capabilities, and Jurox, which expanded anesthetics and pain management offerings. Zoetis continues investing in digital technologies, diagnostics integration, genetic testing, and data-driven animal health platforms intended to support veterinarians and livestock producers with predictive and preventive care tools. Company filings and investor presentations consistently identify innovation, geographic expansion, and portfolio diversification as central strategic priorities.

Geographic Footprint

Zoetis is headquartered in Parsippany, New Jersey, United States, and maintains a broad international presence across North America, Europe, Asia-Pacific, Latin America, the Middle East, and Africa. The company markets products in more than 100 countries and operates manufacturing and research facilities across multiple continents. The United States remains its largest single market, though international operations contribute a substantial portion of total revenue.

The company’s commercial footprint includes developed veterinary markets such as the United States, Canada, Western Europe, Australia, and Japan, alongside emerging growth markets in China, Brazil, and other parts of Latin America and Asia-Pacific. Zoetis maintains regional distribution, regulatory, and technical support capabilities to adapt products and services to local animal health needs and production systems. Its global scale and diversified geographic exposure are frequently cited in public filings as competitive strengths.

Leadership & Governance

Zoetis operates under a corporate governance structure led by an independent board of directors and executive leadership team focused on innovation, operational execution, and long-term shareholder returns. Management has consistently emphasized science-driven product development, veterinary customer engagement, and disciplined capital allocation. Public statements and annual reports indicate the company’s leadership strategy centers on expanding the companion animal portfolio while maintaining a diversified livestock business.

Key executives include:

• Kristin Peck – Chief Executive Officer
• Wetteny Joseph – Executive Vice President and Chief Financial Officer
• Roxanne Lagano – Executive Vice President and Chief Human Resources Officer
• Keith Sarbaugh – Executive Vice President and Chief Compliance Officer
• Jeannette Ferran Astorga – Executive Vice President, Corporate Affairs and Chief Sustainability Officer
• William F. Carapezzi Jr. – Executive Vice President, Business Operations
• Amit Karim – Executive Vice President and Group President, International Operations, Aquaculture and Global Diagnostics

The company’s governance framework and executive compensation practices are disclosed through annual proxy filings and other regulatory submissions. Leadership communications consistently emphasize research investment, operational resilience, sustainability initiatives, and expansion in veterinary innovation markets.